CD4 and infection: At day 6 post infection, ruxolitinib and tofacitinib (0.1, 1.0, and 10 μM) significantly (p < 0.05) reduced extracellular p24 production (Fig 2C) as well as the frequency of HIV-GFP+ CD4+ cells (Fig 2D).